Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Operations: 2021-2025

Historic Cash from Operations for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$35.0 million.

  • Prime Medicine's Cash from Operations fell 35.22% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 40.39%. This contributed to the annual value of -$122.9 million for FY2024, which is 25.72% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Cash from Operations is -$35.0 million, which was up 15.39% from -$41.4 million recorded in Q2 2025.
  • Prime Medicine's Cash from Operations' 5-year high stood at $16.2 million during Q4 2024, with a 5-year trough of -$67.7 million in Q1 2024.
  • Over the past 3 years, Prime Medicine's median Cash from Operations value was -$41.4 million (recorded in 2025), while the average stood at -$37.6 million.
  • In the last 5 years, Prime Medicine's Cash from Operations plummeted by 132.90% in 2022 and then skyrocketed by 137.03% in 2024.
  • Quarterly analysis of 5 years shows Prime Medicine's Cash from Operations stood at -$13.2 million in 2021, then tumbled by 132.90% to -$30.7 million in 2022, then plummeted by 42.82% to -$43.9 million in 2023, then spiked by 137.03% to $16.2 million in 2024, then slumped by 35.22% to -$35.0 million in 2025.
  • Its last three reported values are -$35.0 million in Q3 2025, -$41.4 million for Q2 2025, and -$48.9 million during Q1 2025.